Hair Relaxer Lawsuit Updates

By David Meldofsky, California-licensed attorney · Founder, Lawsuit Informer

Last updated:

This case is one of 17 we track. See where each one stands →

Congress is weighing a bill tied to this case. See where it stands →

2 state laws touch this case. See what each one does →

Where the case stands
Court
MDL 3060, N.D. Illinois, before Judge Mary M. Rowland
Pending cases
12,743 pending, per the JPML report dated November 2, 2026
Current stage
In rulings on October 22 and November 12, 2026, the judge allowed six of the plaintiffs' cancer experts to testify, one of them in part, and excluded two.
First federal trial
Set for September 7, 2027. The five test cases are chosen: Boatwright, Chattman, Fennell, Ford and Smith.
Latest development
On November 16, 2026, L'Oréal and other companies settled the first hair relaxer trial, in Illinois state court in Chicago. The amount is confidential.

No global settlement has been announced and no plaintiff has been paid through the MDL.

On October 22, 2026, Judge Mary Rowland ruled that the plaintiffs' epidemiologist may tell a jury that hair relaxers can cause uterine and ovarian cancer. She let their toxicologist explain how the chemicals could do that, and barred him from giving his own opinion that relaxers cause cancer. The companies had asked her to keep both experts out.

On November 12, 2026, she ruled on six more of the ten experts the companies challenged. Four may testify, including two cancer doctors who say relaxers can cause uterine and ovarian cancer. Two may not. Her two orders now cover eight of the ten.

The ruling clears the biggest hurdle between 12,743 federal cases and a trial. The first federal trial is set for September 7, 2027, and the court has named the five cases that will go first. The first trial in any court began in Chicago state court on November 9, 2026. L'Oréal and other companies settled it a week later for an amount kept private. No settlement covers the federal cases, and nobody has been paid through them. This page follows those developments as the court record changes.

If you used hair relaxer products for years and were later diagnosed with uterine, endometrial, or ovarian cancer, you can ask for a free case review. Whether that history supports a claim depends on your diagnosis, the products you used, and how long ago it was. Pick the diagnosis that fits:

Fibroid claims run on a different track; see Hair Relaxers and Fibroids. Free and no obligation. Deadlines are set by your state and can run from the date of diagnosis. Submitting a review request does not create an attorney-client relationship.

On this page
Important notice

This page provides general educational information about public developments in the hair relaxer litigation. It does not constitute legal advice or medical advice. Case counts and deadlines come from public court reporting and can change.

Hair Relaxer MDL 3060 Case Count and Current Status

The federal hair relaxer cases are grouped together before one judge in Illinois, Judge Mary M. Rowland, in what the courts call MDL 3060. As of November 2, 2026 there were 12,743 still pending, up from 12,381 in October and 12,129 in September. That makes it the fourth-largest group of federal cases of its kind. Counts move month to month as new cases are filed and others are closed or combined.

The companies being sued are the makers and sellers of the relaxer brands. The order that created the MDL in February 2023 named nine company groups. The defense side has grown well past that since. More than twenty companies appear on current court filings, including:

Revlon is in bankruptcy. The court has kept the cases against it moving under orders from the bankruptcy court.

These cases are no longer new. Both sides have spent 2026 gathering evidence and preparing the first cases for trial. In January 2026 the court held a "Science Day," a session where each side walked the judge through the research. Most of the year since went to the fight over which scientists each side may put in front of a jury. On October 22 the judge gave her first answer.

The claims themselves come down to a few questions. Were the products designed safely. Did the labels warn about what the chemicals could do. Does frequent use over years raise the risk of cancer. Did the companies tell buyers what the research showed.

The research at the center of it is a 2022 analysis from the National Institutes of Health Sister Study. Of women who never used straighteners, an estimated 1.64% would develop uterine cancer by age 70. Among frequent users the estimate was 4.05%, roughly two and a half times as often. Those are the numbers both sides are fighting over. For the science the court is weighing, see The Hair Relaxer Cancer Studies, Explained, and for the underlying causation question see Does Hair Relaxer Cause Cancer?

Hair relaxer claims are still being filed. If you used hair relaxer products and were later diagnosed with uterine, endometrial, or ovarian cancer, you may qualify for a free case review. Fibroid-related claims are generally handled differently; see Hair Relaxers and Fibroids.

Check My Eligibility

What has happened recently

In Congress

Congress has one bill on hair relaxers.

The Healthy Hair Act, H.R. 7685, would bar the sale of any hair straightening or smoothing product that contains formaldehyde or a chemical that releases it. The rule would cover relaxers and keratin treatments shipped starting 180 days after the bill became law. The bill would also have the FDA study the health effects of these products, including on salon workers. Representative Brown filed it on February 25, 2026, with 12 cosponsors. It sits in the House Energy and Commerce Committee, where it was sent the same day.

The bill covers which hair products can be sold from here on. The hair relaxer lawsuits on this page run on their own track. The bill becomes law only if both chambers pass the same text and the President signs it.

In the States

Two states have passed laws on hair relaxers.

New York Governor Kathy Hochul signed Assembly Bill 1797 on November 21, 2025. A hair relaxer sold in New York must carry a warning label if it contains a chemical known to cause cancer or reproductive harm. The label rule starts 18 months after the signing, in May 2027. The state attorney general enforces it.

California’s C.U.R.L. Act, Senate Bill 236, became law on October 11, 2025. It bars making or selling hair relaxers that contain certain listed chemicals. Formaldehyde is one of them. A state agency, the Department of Toxic Substances Control, enforces the ban. The agency must publish the tests it will use by January 1, 2028.

These laws cover which products can be sold and how they are labeled from here on. The lawsuits on this page are about harm that already happened, and they run on their own track. Our state laws page tracks both laws.

What the judge's expert rulings mean

In a case like this, the judge decides before trial which scientists a jury is allowed to hear. If the plaintiffs' experts are kept out, the plaintiffs have no way to prove that relaxers cause cancer, and the cases end. That is why both sides spent most of 2026 on this fight, and why these rulings matter more than anything else on this page.

The companies asked the judge to exclude all ten of the plaintiffs' general causation experts. General causation means whether the products can cause these cancers at all, as opposed to whether they caused one woman's cancer. The companies argued that the experts leaned on weak epidemiology, on exposure data that does not apply to real use, and on unproven theories about hormone-disrupting chemicals.

On October 22, 2026, Judge Rowland answered the companies' arguments that applied to all ten experts, and ruled on two of them by name. The 65-page opinion is docket entry 2079. A second order, on November 12, decided six of the other eight.

The judge rejected the companies' across-the-board arguments. The plaintiffs' experts may treat a relaxer as a mixture and reason from groups of chemicals that act the same way. They do not have to name the one ingredient, or the exact recipe, that causes the harm.

The judge also refused to throw out the three studies at the center of the case. She said the companies' complaints about those studies are for a jury to weigh. Each expert still has to show a reliable method for every step of their reasoning.

Dr. Cote, the plaintiffs' epidemiologist, may testify in full. She concluded that chemical hair relaxers, taken as a whole product, can cause uterine and ovarian cancer. The judge found her method reliable and left the companies' disagreements with her conclusions for cross-examination.

Mr. Atwood, a toxicologist, may explain how the chemicals in relaxers could cause these cancers. He may describe absorption through the scalp, the combined effect of hormone-disrupting chemicals, and effects at low doses.

The judge cut four parts of his testimony. He may not give his own opinion that relaxers cause cancer. He may not rely on breathing in the chemicals as a separate route of exposure. He may not use formaldehyde or other known carcinogens as part of his mixture theory, because his report did not tie them to these cancers. He may not opine on broad ingredient groups like fragrances and UV filters.

On November 12, 2026, Judge Rowland issued the second order, docket entry 2092. The 29-page opinion rules on six more experts. Four may testify and two may not.

Dr. Roque and Dr. Sharma are gynecologic oncologists, doctors who treat cancers of the uterus and ovaries. Each concluded that chemical hair relaxers can cause those cancers. The companies argued that neither specializes in studying disease across large groups of people. The judge found both qualified by their training and clinical work, and found their methods reliable.

Dr. Panigrahy may explain how the chemicals in relaxers could cause cancer. He may also give his own conclusion that relaxers can cause uterine and ovarian cancer. Dr. Brown, a dermatologist, may explain how relaxer chemicals can pass through the scalp and into the body.

The judge excluded two experts. Dr. Chang is a fertility specialist, and the judge found that his training does not cover what causes these cancers. Dr. Pugliese is a dermatologist. The judge found that her report did not explain the method behind her review of the research.

The judge wrote that her rulings on these experts cover uterine and ovarian cancer only. They do not cover other health conditions in these cases.

The rulings do not decide any woman's case. They mean a jury will be allowed to hear the plaintiffs' core science. The judge has ruled on eight of the ten experts the companies challenged. She has not yet ruled on the companies' own experts.

The state lawsuits against L'Oréal

On September 10, 2026, Arizona's attorney general, Kris Mayes, sued L'Oréal and its hair care company SoftSheen-Carson in state court in Phoenix. The state says the companies sold chemical relaxers to Black women and girls in Arizona for decades while calling them safe and gentle. It says they never told buyers about research linking frequent relaxer use to uterine and ovarian cancer.

The products named include Dark & Lovely, Optimum and Mizani. The state's complaint also lists Bantu, Care Free Curl, Look of Radiance, Roots of Nature and Ultra Precise. It points to Dark & Lovely Beautiful Beginnings as a line sold for children. You can read the state's complaint (PDF, 25 pages).

Arizona is asking the court for three things:

L'Oréal told Consumer Reports that its products are safe and that the lawsuit has no legal or scientific merit. The company says the study behind the case called for more research and did not find that relaxers cause cancer. Reuters reported that Arizona is the first state to sue over hair relaxer cancer risk.

On October 23, 2026, Minnesota’s attorney general, Keith Ellison, sued L’Oréal over the same three brands. Minnesota says the company marketed the relaxers to Black women and girls as safe and kept the cancer risks to itself. The state says that broke three Minnesota consumer protection laws.

Minnesota is asking for fines, money back for Minnesota buyers, and an order stopping sales without health warnings. The claims have not been proven in court.

What the Arizona case means for women with cancer

Arizona brought this case as the state, on behalf of its residents as a whole. It is about how the products were sold and labeled in Arizona. Women diagnosed with cancer bring their own cases, for their own diagnosis and their own losses. Those cases continue in federal court and in several state courts.

Whether your own history supports a case depends on your diagnosis, the products you used, and when you used them. A free case review can look at those facts.

Arizona’s case is the state suing on behalf of its residents. It does not pay individual women. A personal claim runs separately, and whether a history of relaxer use supports one depends on the diagnosis, the products, and the dates.

See If My Situation Qualifies

A separate track for women who have not been diagnosed

Most of this page is about women who were diagnosed with cancer. There is a second request in front of the judge that works differently.

Plaintiffs have asked the court to certify medical monitoring classes. A medical monitoring claim asks a company to pay for regular screening for people who were exposed to something and face a raised risk, before any diagnosis. The companies oppose it, and they have also asked the judge to throw out the doctors the plaintiffs rely on to support it. Briefing finished in early September 2026 and the judge has not ruled.

Whether this track goes anywhere is unsettled, and it is separate from an individual claim for a cancer diagnosis. Nothing about it has been decided.

Has there been a settlement?

Four women have settled so far. Their cases were the first hair relaxer cancer cases to reach trial. The women sued L'Oréal and other companies in Illinois state court in Chicago in 2023 and 2024. Each says years of chemical straighteners led to a gynecologic cancer, a cancer of the reproductive organs. Jury selection began on November 9, 2026, and the women settled on November 16. The amount is confidential.

L'Oréal said it remains confident in the safety of its SoftSheen-Carson products, which include its relaxers. The settlement covers those four women only. No global settlement or fund covers the 12,743 federal cases, and nobody has been paid through them.

A court-appointed official is still coordinating settlement talks across the federal cases and the state cases in Illinois, Philadelphia, Georgia and New York. Those talks have not produced a deal for the cases as a whole.

The clearest public signal came on July 24, 2026, when the judge refused to extend the pause protecting one group of companies. They had asked for more time while private talks continued. The court put them back into the ordinary process instead, which means the case is moving forward rather than waiting on a deal.

Be careful with settlement figures

The only settlement so far, in the Chicago trial, kept its amount private. That leaves no public hair relaxer settlement amounts and no per-person payout figures. Any dollar figure you see quoted for this case is an estimate, or a comparison borrowed from a different lawsuit. No court has approved a number here.

In cases like this, values are usually not set until after the judge finishes ruling on the science and the first test trials happen. The judge has ruled on eight of the plaintiffs' ten experts so far. The first federal trial is set for September 7, 2027.

What these updates mean for a claim

Updates like these show whether a case is still growing, whether big rulings are going one way or the other, and whether trials are getting closer. What they do not do is predict what happens to any individual claim.

It is also worth separating two things. The case moving through court is one question. Whether the science shows hair relaxers cause cancer is a different one, and it is still contested. See Does Hair Relaxer Cause Cancer? for that.

Deadlines do not wait for the court to rule. The filing window is set by your state and can start running from the date of diagnosis, not from whenever the MDL reaches a verdict. A free review can tell you where that leaves you.

Check My Filing Deadline

What to watch next

The court reset this schedule in late August 2026, and three dates now matter more than the rest. Expert evidence-gathering in the five test cases closes on December 21, 2026. The motions that could narrow or end parts of the case are due January 11, 2027, with briefing on them finishing February 24, 2027. Those rulings will shape the litigation more than anything else on this list.

When will the first trials start?

Courts handling thousands of similar cases pick a few to try first. Lawyers call them bellwether trials, and both sides watch them to work out what the evidence is worth and how juries react.

The first federal trial is set for September 7, 2027. The court has built its 2027 calendar around that date, with case management conferences scheduled every month from January through August. A state court in Chicago went first. Its trial of four women's cases began on November 9, 2026, and ended in a settlement on November 16.

The pool of cases has been narrowed three times. Thirty-two cases went into the first round of evidence-gathering, which closed on March 18, 2026. On April 2, 2026 the judge cut that group to ten. The court then ordered the two sides to propose how to cut the ten to five by October 21, 2026.

On October 22 the judge entered their agreed list: the cases of Bridget Boatwright, Carrie Chattman, Charlene Fennell, Gloria Ford and Karla Smith. Four are uterine cancer cases. The Ford case is the one ovarian cancer case, and it runs on a delayed schedule behind the other four.

A date on the calendar is not a promise. Trial dates in cases this size move. The judge has ruled that six of the plaintiffs' experts may testify, one of them in part, and excluded two. Rulings still to come could reshape what a trial looks like.

For background on the research the court is weighing, see The Hair Relaxer Cancer Studies, Explained.

How This Page Fits With Our Main Hair Relaxer Coverage

The main Hair Relaxer Cancer Lawsuit page explains the broader allegations, products, health concerns, and claim categories commonly discussed in this litigation. Four companion pages cover the science and health questions in plain English. Does Hair Relaxer Cause Cancer? takes the causation question directly. The Hair Relaxer Cancer Studies, Explained walks through the research. Hair Relaxers and Fibroids covers the separate fibroid claims. Are Hair Relaxers Safe? looks at the products themselves.

This page is narrower. It focuses on procedural developments and public case updates rather than the broader educational overview.

Related Lawsuit Topics

Hair Relaxer Cancer Lawsuit

Read the broader overview of hair relaxer allegations, product history issues, and health concerns discussed in these claims.

Does Hair Relaxer Cause Cancer?

What the research does and does not say about chemical hair relaxers and cancer, in plain English.

The Hair Relaxer Cancer Studies

The 2022 NIH Sister Study and related research that form the scientific backdrop to this litigation.

Hair Relaxers and Fibroids

A separate condition from the cancers at the center of the MDL, and how fibroid claims are generally handled differently.

Are Hair Relaxers Safe?

The reported risks, the chemicals that have drawn scrutiny, and how to think about personal risk.

Mass Torts

Understand how large coordinated proceedings work when many similar claims are handled together.

Find Out If You May Have a Case

If you used chemical hair relaxers for years and were later diagnosed with uterine, endometrial or ovarian cancer, you can request a free case review on Lawsuit Center. There is no obligation. Fibroid claims are usually handled differently, and a review can explain how a situation fits.

Educational purposes only. Submitting a case review request does not create an attorney-client relationship.

David Meldofsky

About the Author

David Meldofsky is a California-licensed attorney and the founder of Lawsuit Informer, an educational platform focused on helping people understand lawsuits, consumer safety issues, and legal rights related to defective products and toxic exposures.

Learn more about our Editorial Policy or Contact us.

Last Updated:

Educational information only. Not legal advice. No attorney-client relationship is formed.